MetaCap

BridgeBio Oncology Therapeutics (BBOT) vs Oramed Pharmaceuticals (ORMP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oramed Pharmaceuticals (ORMP) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, gaining 38.4% versus a loss of 85.4%. Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $145.3 million), about 1.1 times the size. On valuation, Oramed Pharmaceuticals trades at a lower trailing P/E (1.0x vs 3.4x for BridgeBio Oncology Therapeutics).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBOT-85.39%ORMP+38.37%
+117%+11%-95%
Nov 21, 20251 yearNov 20, 2026
BBOT-82.24%ORMP+25.26%
+84%-3%-90%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBOT versus ORMP key metrics
MetricBBOTORMP
Share price$1.81$3.57
Market cap$145.25M$155.24M
1-day change-2.69%-3.25%
YTD return-85.54%+25.26%
1-year return-85.39%+38.37%
5-year return—-82.34%
P/E ratio (TTM)3.421.05
EPS (TTM)$0.53$3.41
Dividend yield0.00%7.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.00M
Net income (latest FY)$-134.04M$64.05M
Gross margin—0.65%
Operating margin—-754.40%
Net margin—3202.50%
52-week high$14.87$5.47
52-week low$1.79$2.52
Distance from 52-week high-87.83%-34.73%
Analyst consensusstrong_buynone
Avg. price target upside+1060.22%+96.08%
Average volume631.56K173.38K
Shares outstanding80.25M43.49M
Employees92—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ORMP has outperformed BBOT by 123.8 percentage points over the past year.
  • BridgeBio Oncology Therapeutics trades at a higher earnings multiple (3.4x vs 1.0x trailing P/E).
  • Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).

About BridgeBio Oncology Therapeutics

BBOT stock →

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About Oramed Pharmaceuticals

ORMP stock →

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Health Care · Biotechnology: Pharmaceutical Preparations

BBOT vs ORMP FAQ

Which is bigger, BridgeBio Oncology Therapeutics or Oramed Pharmaceuticals?

Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).

Which stock has performed better over the past year, BBOT or ORMP?

ORMP returned +38.37% over the past 12 months, compared with -85.39% for BBOT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BBOT or ORMP?

ORMP has the lower trailing P/E at 1.0, versus 3.4 for BBOT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, BridgeBio Oncology Therapeutics or Oramed Pharmaceuticals?

Oramed Pharmaceuticals pays a dividend yielding 7.00%, while BridgeBio Oncology Therapeutics does not currently pay a regular dividend.

Are BridgeBio Oncology Therapeutics and Oramed Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons